Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Strategic Alliance Partners

June 04, 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

June 03, 2023

Radium-223 was safe and did not preclude patients with metastatic castration-resistant prostate cancer from receiving subsequent life-prolonging therapies, including chemotherapy.

June 02, 2023

Closing out their panel on immunotherapy in non–small cell lung cancer, expert oncologists share key takeaways on the selection of novel therapy in this setting.

May 26, 2023

A brief review of the POSEIDON trial, which analyzed durvalumab with or without tremelimumab in combination with chemotherapy in advanced NSCLC.

May 26, 2023

Key opinion leaders in the field of non–small cell lung cancer management discuss the role of immunotherapy in patients with concomitant KRAS and KEAP1/STK11 mutations.

May 19, 2023

A comprehensive discussion on combination chemotherapy + immunotherapy regimens available to patients with advanced non–small cell lung cancer.

May 19, 2023

Shared insight on the value that molecular testing and PD-L1 testing, respectively, have on determining optimal therapy for patients with advanced non–small cell lung cancer.

May 12, 2023

Switching their focus to advanced non–small cell lung cancer, panelists identify parameters that may influence the use of immune checkpoint inhibitors in this setting.

May 10, 2023

Tania Jain, MBBS, discusses notable differences in baseline characteristics and donor sequencing, according to a retrospective study of patient outcomes following blood or marrow transplant in 4 common donor types of myelofibrosis.

April 28, 2023

Expert oncologists reflect on key factors that aid in the selection of therapy for patients diagnosed with resectable non–small cell lung cancer (NSCLC).

April 13, 2023

Amanda Nickles Fader, MD, discusses the randomized, phase 3 NRG-GY019 trial evaluating letrozole with or without paclitaxel and carboplatin in patients with stage II to IV primary low-grade serous carcinoma of the ovary or peritoneum.

March 30, 2023

Meghan K. Berkenstock, MD, discusses common ocular toxicities associated with the use of novel antibody-drug conjugates, and the subsequent development of mitigation strategies for these treatment-related adverse effects in gynecologic cancers.

March 28, 2023

Meghan K. Berkenstock, MD, discusses the management of antibody-drug conjugate-related ocular toxicities in gynecologic cancers.

March 23, 2023

Julie Renee Brahmer, MD, discusses the use of tremelimumab plus durvalumab and platinum-based chemotherapy for the first-line treatment of patients with non–small cell lung cancer, and how decisions can be made between this regimen and nivolumab plus ipilimumab and chemotherapy.

March 16, 2023

Jean Wright, MD, discusses the benefit of moderate hypofractionation in patients for adjuvant radiotherapy in patients with early-stage breast cancer.

March 16, 2023

Michael A. Carducci, MD, discusses the significance of two ongoing clinical trials in prostate cancer: the phase 3 CAPItello-280 trial (NCT05348577) and phase 3 INDICATE study (EA8191; NCT04423211).

March 16, 2023

The combination of nivolumab and relatlimab demonstrated clinical benefit with a manageable safety profile in patients with advanced melanoma who have progressed on prior PD-L1 or PD-1 inhibitors, regardless of PD-L1 and LAG-3 expression, according to findings from the ongoing phase 1/2a RELATIVITY-020 trial.

March 08, 2023

Julie Renee Brahmer, MD, discusses clinical trials investigating treatment options for patients with non–small cell lung cancer following progression after first-line immunotherapy.

March 06, 2023

Tania Jain, MBBS, discusses the unmet needs for patients with myelofibrosis who receive an allogeneic stem cell transplant.

February 28, 2023

With acquired resistance patterns emerging for nearly every agent, hematologic experts are looking closely at sequencing patterns, but more work needs to be done in aggressive malignancies in which mutations associated with resistance may be present before therapy even begins.